View all veterinary jobs
Boehringer Ingelheim Vetmedica has launched Equisolon 33 mg/g oral powder, the first licensed oral prednisolone for the alleviation of inflammation associated with recurrent airway obstruction (RAO), otherwise known as heaves, in horses.
Clare Turnbull, equine brand and technical manager at Boehringer Ingelheim Vetmedica said: "Oral glucocorticoids are sometimes necessary for treating the inflammation associated with RAO. We feel it is important that when our customers need to use prednisolone for their cases, there is an equine specific product available to them that is easy to dispense and administer."
The company says Equisolon should be used in combination with environmental measures to treat RAO.
For further information on Equisolon, contact your Boehringer Ingelheim Vetmedica equine representative or call +44 (0)1344 746959.
Boehringer Ingelheim Vetmedica has launched trial size Seraquin dispensing strips so clients can try a week's supply of the veterinary joint support supplement for cats and dogs.
Rob Lucy, brand manager for Seraquin, said: "With 9 out of 10 dogs and cats eating Seraquin as a treat, the new dispensing strips are a great way to enable pet owners to experience just how palatable it is."
Each pack of Seraquin dog dispensing strips contains 40 strips of 10 chewable tablets. Each pack of Seraquin cat and small dog dispensing strips contains 10 strips of 20 chewable tablets.
Boehringer says that for each pack of Seraquin dog dispensing strips purchased, veterinary practices will get one pack of Seraquin cat and small dog dispensing strips free. In addition, the company will make a £20 donation to Hounds for Heroes on behalf of each practice that orders Seraquin Dispensing Boxes. The donations will help to buy, train and support an assistance dog for an injured or disabled man or woman from the UK armed forces or civilian emergency services.
For further information, contact your Boehringer territory manager.
Boehringer Ingelheim Vetmedica has launched Semintra, a new liquid treatment for cats with chronic kidney disease (CKD).
The active ingredient in Semintra is telmisartan, the first angiotensin receptor blocker to be licensed in veterinary medicine.
Like benazepril, Semintra is indicated for the reduction of proteinuria associated with CKD in cats. Boehringer says it has a highly targeted mode of action that provides rapid and reliable reduction of proteinuria in cats with chronic kidney disease. The company adds that it is well tolerated and almost exclusively excreted in the faeces, so elimination is not dependent on renal function.2
Above all, Boehringer is highlighting the how easy the treatment is to use, pointing to a study that has shown it is well accepted by more than 90% of cats.1,3
Martha Cannon, RCVS Specialist in Feline Medicine at the Oxford Cat Clinic, has already used Semintra in cats with CKD. She said: "For us at the Oxford Cat Clinic, ease of use is an enormously important part of any product that we use for cats. From our personal experience, we found that Semintra is very well accepted by cats, with owners finding it very easy to give and to build into their cat's daily treatment plan."
Semintra is available from veterinary wholesalers as a 4mg/ml oral solution. There is one 30 ml bottle size which will last the average 4kg cat 30 days.
A few CKD facts provided by Boehringer:
For further information on Semintra visit www.semintra.co.uk, contact your local Boehringer Ingelheim territory manager or telephone +44 (0)1344 746959.
References
Boehringer Ingelheim Vetmedica has launched Pexion (imepitoin) a novel treatment for canine idiopathic epilepsy.
Canine epilepsy can affect up to 5% of dogs6. In most dogs diagnosed with idiopathic epilepsy no underlying cause for the seizures can be found. While the condition can affect any dog, it is more common in young (one to five year old), purebred dogs such as Labradors, Golden Retrievers, German Shepherds, Boxers, Vizlas, Beagles, English Springer Spaniels, Irish Setters, Poodles and Dachshunds.
Boehringer says Pexion has a highly targeted mode of action1-3 to suppress a dog's seizures. It starts to work within a few hours and reaches steady state within three days4,5. Boehringer claims this will make it easier to stabilise epileptic patients. It also says there is no evidence of hepatotoxicity or liver-associated enzyme elevation, so repeated blood tests for liver enzymes or therapeutic levels are no longer required.4,5
Pexion is available in 100 mg and 400 mg tablets. The tablets are white, scored and divisible in half. Both tablet strengths are available in 100 tablet packs from veterinary wholesalers.
Jemima Mead, brand manager at Boehringer said: "Pexion is a ground-breaking new product which gives vets a new first-line treatment option for dogs with idiopathic epilepsy, improving the lives of newly diagnosed epileptic dogs and their owners by reducing the number of seizures and their impact on the patient's life".
To support the launch of the new product, Boehringer hosted an epilepsy webinar presented by neurologist Dr Holger Volk DVM PhD DipECVN FHEA MRCVS, recognised RCVS and European Specialist in Veterinary Neurology. The webinar is now available on demand at www.bi-academy.co.uk.
For further information on Pexion visit www.pexion.co.uk, contact your local Boehringer Ingelheim territory manager or telephone +44 (0)1344 746959.
According to the company, the new injectable form of Vetmedin provides rapid acting treatment for canine congestive heart failure originating from valvular insufficiency (e.g. mitral valve disease, MVD) or dilated cardiomyopathy (DCM). Twelve hours after the injection is administered, treatment can be continued by the dog's owner with Vetmedin flavour tablets or Vetmedin hard capsules at the recommended dosage.
Ruth Willis BVM&S DVC MRCVS, RCVS Recognised Specialist in Cardiology said: "Parenteral administration of medicines is often preferred in cases of acute congestive heart failure to help minimise patient stress and clinical deterioration. Vetmedin Solution for Injection is therefore a useful addition to our armoury of products for the treatment of acute congestive heart failure due to MVD or DCM."
The injection contains 0.75 mg/ml of the active ingredient, pimobendan, and it is supplied in 5 ml single use vials at the licensed dose of 0.15 mg/kg, with one vial treating a dog up to 25 kg.
In association with the Vets Now emergency treatment service, Boehringer has produced an algorithm which features step-by-step guidance on the recommended treatment protocol for dogs with acute congestive heart failure due to MVD or DCM, together with point of sale material including shelf wobblers for use in practice to raise awareness of the product.
The company is also hosting a free cardiology webinar presented by Ruth Willis entitled 'Acute CHF - a stress free approach'. The online seminar takes place at 8.00pm on Tuesday 19 February and counts for one hour's CPD. The webinar will be available to view after the live event on demand. To register, visit http://www.bi-academy.co.uk/.
For further information, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
Boehringer Ingelheim Vetmedica has released data which shows that one third of laminitic middle aged horses (between the ages of 10 and 15 years) test positive for PPID (Cushing's)1.
Over 3,100 horses were tested for Cushings as part of the company's 'Talk about Laminitis' campaign during the spring.
Liz Barrett, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Although the common perception is that PPID is a disease of only older horses and ponies, the ageing process is progressive and this data from over 330 participating veterinary practices1 indicates that horses and ponies in the 10 to 15 age bracket are also frequently affected."
The company is urging veterinary surgeons to test laminitic or foot-sore horses for PPID this autumn, as this is when there is a greater difference between horses with PPID and those free of the disease2, 3. In support of this, Boehringer will be re-launching its disease awareness initiative 'Talk About Laminitis', with free ACTH blood tests* during September, October and November. To participate in the scheme, veterinary surgeons can download free ACTH blood test vouchers from http://www.talkaboutlaminitis.co.uk/.
Dr Catherine McGowan BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS from the University of Liverpool, said: "It is very important to test horses for PPID the first time they present with laminitis because what we want to avoid is recurrence of that laminitis. If it does reoccur, the damage will be worse and the chances of that horse having a successful long-term recovery will be diminished."
For further information on 'Talk About Laminitis', PPID or Prascend, visit www.talkaboutlaminitis.co.uk, contact your Boehringer territory manager or call 01344 746959.
Boehringer Ingelheim Vetmedica has launched a new Canikur Pro website - www.canikurpro.co.uk - to provide pet owners with advice on digestive upset and offer a quick reference guide to using Canikur Pro.
The site offers information about the common causes of digestive upset, including dietary indiscretions, stress due to a change in circumstances and underlying gut problems.
The site also contains information about how Canikur Pro works, how to give the product and where to buy it, plus tips for supporting the recovery of a dog's gut health such as providing a constant supply of fresh water, offering a bland diet and providing access to outside areas to reduce accidents.
In addition, the site contains a 'veterinary only' area where veterinary professionals can download client materials.
Boehringer Ingelheim Vetmedica has extended its Metacam 0.5 mg/ml Oral Suspension for Cats range with the launch of a 30ml bottle size, which the company says will last the average 5 kg cat for two months.
According to Boehringer, the new 30ml bottle will offer owners a cost saving compared to purchasing two 15 ml bottles. In addition, it will provide greater prescription options for veterinary practices currently stocking 3ml and 15 ml bottles,,
Andrew Francis, Metacam brand manager said: "The new 30ml bottle of Metacam Oral Suspension for Cats will provide both veterinary practices and their clients with a product that is great for the long-term treatment of chronic pain in cats in one convenient pack."
For further information on Metacam, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
Boehringer Ingelheim Vetmedica has launched Benefortin (benazepril hydrochloride), an ACE inhibitor licensed for the treatment of congestive heart failure (CHF) in dogs. It is also licensed for the treatment of chronic renal insufficiency (CRI) in cats.
Benefortin uses novel micro-cap technology to mask the taste of the bitter molecule. According to Boehringer, this ensures that Benefortin tastes good1, even if it is bitten, crunched or chewed. The company says taste tests demonstrated 100% palatability in dogs and 92% palatability in cats in home settings1.
Benefortin is available in 5mg and 20mg tablets for dogs and 2.5mg tablets for cats and dogs.
Jemima Scott, Boehringer Ingelheim brand manager said: "The addition of Benefortin to our cardiology portfolio now enables us to provide veterinary practices with two of the cornerstones of canine CHF treatment, and the palatability of Benefortin makes it an excellent choice for vets needing to prescribe an ACE inhibitor."
To support the launch of Benefortin, Boehringer is offering veterinary practices the opportunity to win one of three Bosch microwave ovens in a prize draw by answering three multiple choice questions on the ACE inhibitor.
For further information on Benefortin, contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
A new quarterly veterinary publication - Companion Animals - has been launched to provide veterinary professionals with a structured summary of the best international literature published in the past three months.
The peer-reviewed publication is backed by an educational grant from Boehringer Ingelheim Vetmedica, which says it is part of the company's commitment to invest in education and continue to support vets in practice.
Companion Animals contains expert commentary and analysis on recent advances in veterinary medicine and has an international editorial and advisory board. The board comprises Virginia Luis Fuentes from the Royal Veterinary College, Daniel Holden from the County Veterinary Clinic, Jacques Penderis from the University of Glasgow, Scott Brown from the University of Georgia, Brice Reynolds from the National Veterinary School of Toulouse, Rob Rayward from Coast Veterinary Referrals, James Oliver from North Kent Referrals, Sarah Smith from Sarah Smith Cardiology, Mark Lowrie from Davies Veterinary Specialists, Marieke De Vries from the Animal Health Trust and Patricia Ibarrola from University College Dublin.
In addition, each issue contains an original review article. The leading article in Volume 1, Issue 1 is titled 'The recognition and management of acute and chronic pain in cats' and is authored by Louisa Slingsby from the University of Bristol.
To register an account and receive all content free of charge, courtesy of Boehringer Ingelheim Vetmedica, please contact your local Boehringer Ingelheim Vetmedica territory manager or telephone 01344 746959.
The Heart Health Panel - a group of expert veterinary surgeons, cardiologists and nutritionists set up by Boehringher Ingelheim Vetmedica - has launched a set of guidelines on the management of canine cardiac health through nutrition and lifestyle changes.
Entitled Supporting canine heart health through nutrition and lifestyle, Boehringher says the guidelines provide veterinary professionals with information on canine heart health, including the progression of heart disease through four main stages. These are: the green phase - no clinical signs and no pathology; the yellow phase - no clinical signs of heart failure but evidence of disease at clinical exam; the orange phase - occasional clinical signs when exercising and the red phase - clinical signs at rest.
The panel has developed a diagnostic checklist to determine whether a patient has heart disease and which phase they are in to help initiate a good diet and healthy lifestyle early enough to support heart health. While a dog's individual needs should be taken into account when advising on dietary management and lifestyle, the panel's recommendations include a balanced, complete diet, dietary supplements, such as omega-3, and an appropriate exercise regime.
The Heart Health Panel's guidelines are now available as a booklet and are supported with a leaflet for dog owners entitled Support your dog's heart. The leaflet features information on canine heart health including risk factors, dietary advice, clinical signs of disease, diagnosis and the creation of a heart health management plan. Both the owner leaflet and the panel guidelines are available from Boehringer Ingelheim Vetmedica, and copies can be ordered from your local territory manager or by emailing vetmedica.uk@boehringer-ingelheim.com.
Boehringer Ingelheim Vetmedica and the Feline Advisory Bureau (FAB) have launched Spot The Signs, a campaign designed to help owners spot the signs of painful, age-related conditions in cats, such as arthritis.
According to the company, which makes Metacam, 46% of cats are now classed as 'mature and older', and 87% of vets have treated cats aged 22 or more. Yet a survey of 3000 cat owners found that 75% would not recognise the signs of chronic pain in their cat. And despite 50% of owners believing that cats suffer pain the same way as humans, 78% of cats had never been taken to the vet for an old age check up.
99% of 77 veterinary surgeons surveyed agreed that chronic pain often goes unnoticed and that signs of pain can be confused with cats simply getting old. When shown a list of common signs of long term pain in cats, 65% of owners recognised at least one of these signs in their own cat.
Claire Bessant, leading feline author and CEO of FAB, said: "In a recent study, 65% of cats aged 12 and above showed evidence of arthritis when X-rayed. The survey also showed that a large proportion of cats do show signs that may be caused by chronic pain, including becoming withdrawn, reduced grooming and reduced activity, but these were not attributed to pain by the owners. Arthritis has only just been recognised by the veterinary profession as a major problem in cats and so it is not surprising that 80% of cat owners do not realise that their cats can develop this painful condition."
Most owners understand that arthritis can cause significant pain and discomfort, and 93% said they would feel guilty if their cat was in pain and they hadn't realised. 65% of Brits see their cat as member of the family, with 20% saying their cat is like a child to them.
The Spot the Signs campaign is being 'fronted' by Jess the Cat, Postman Pat's sidekick, with expert support from a panel of cat medicine and behaviour specialists including leading feline author Claire Bessant and VetSurgeon.org / VetNurse.co.uk blogger, Pete Wedderburn MRCVS. The campaign includes support materials for veterinary practices and a facebook page.
Claire Fowler, Boehringer Ingelheim, said: "Despite a steady increase in the number of cases of arthritis and chronic pain in cats being diagnosed, our research shows awareness amongst cat owners of how to look for pain in their cats remains surprisingly low, despite 86% saying they would want their vet to let them know if their cat might be in pain. For many owners, spotting the signs of pain in their cat can be difficult, so we have set out to educate cat owners about what to look for and to encourage them to consult their vet or vet nurse if they are concerned."
Boehringer Ingelheim VetMedica has published its equine endocrine webinars online for veterinary professionals to view on demand at www.prascend.co.uk/webinars.
The webinars, which cover 'Diagnostic challenges in equine endocrine disease', presented by equine internal medicine specialist Andy Durham from the Liphook Equine Hospital, and 'A problem-based approach to equine laminitis', presented by equine internal medicine specialist Dr Catherine McGowan from the University of Liverpool, are each one hour long.
Participants will each receive CPD certificates for participation.
Boehringer Ingelheim Vetmedica has launched new, more palatable Metacam Chewable Tablets.
According to the company, the tablets are proven to be taken by 90% of dogs voluntarily1 and 80% will even take them from the floor1 which aids compliance. Available in pop-through blister strips of seven for easy dispensing and administration, the 1mg and 2.5mg Metacam Chewable Tablets are packed in boxes of 84 and priced the same per tablet as the current tablet range.
Claire Fowler, companion animal marketing manager at Boehringer Ingelheim, said: "The existing Metacam Chewable Tablets are readily accepted by most dogs. However, to appeal to as many dogs as possible, we have launched an even more appetising 'beefed up' meaty flavour."
For further information on the new flavoured Metacam tablets, including special offers, please contact your Boehringer Ingelheim territory manager or call 01344 746959.
Boehringer Ingelheim Vetmedica has increased its range of marketing and educational materials about heart disease and the use of Vetmedin.
The materials include canine heart disease awareness posters for either the waiting room or consult room which feature 'static cling' technology, enabling them to stick to any surface without adhesive, as well as information leaflets, owner booklets, health diaries and dog tags.
Materials for dog owners are designed to inform about the signs to look out for with heart disease, and the steps involved in the diagnosis and management of the condition. There's a post-prescription owner booklet which features a health diary for dog owners to fill in, allowing them to track any changes in their dog's condition, as well as details on the telltale signs of heart failure and the benefits of Vetmedin.
Also available in the range are materials to help make prescribing the optimum dose of Vetmedin as easy as possible, including dose optimisation mouse mats, dose dials, treatment algorithms and interactive dose calculators on CD for those veterinary practices without internet access.
For further information, please contact your Boehringer Ingelheim Vetmedica territory manager or call 01344 746959.
Boehringer Ingelheim Vetmedica has launched a series of information sheets written by veterinary surgeons, nutritionists and leading riders to support its muscle building supplement for horses, Equitop Myoplast Power Pearls.
Available to download as PDFs from its website - http://www.equitop-myoplast.co.uk - this resource for horse owners covers a range of feeding topics including training the young showjumper and feeding the performance horse, older horses and horses during periods of rest and recuperation.
New video and written testimonials from performance riders and veterinary surgeons are now on the website, which also offers owners advice on healthy lean muscle growth and the benefits of Equitop Myoplast. Olympic dressage rider, Emile Faurie, international showjumpers, Ellen Whitaker and Scott Brash, and show horse producer, Katie Jerram, all endorse the product.
A client leaflet has also been launched featuring the testimonials and providing owners with information on Equitop Myoplast and an online offer of £15 off their first purchase of the supplement by downloading a voucher from the website.
Boehringer says Equitop Myoplast is packed with 18 key amino acids and is scientifically designed to support lean muscle growth, not bulk. The company says the supplement is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
Boehringer Ingelheim Vetmedica has re-launched its Vetmedin website: www.vetmedin.co.uk.
Boehringer says the new site has been designed as a resource for veterinary professionals to help educate clients with dogs suffering from congestive heart failure. It includes an animation about heart disease, together with hints, tips and videos covering exercise, diet, treatment and how to monitor the condition.
To support the relaunch of www.vetmedin.co.uk, Boehringer is offering veterinary professionals a £25 money-off voucher towards the NEW edition BSAVA Manual of Canine and Feline Cardiorespiratory Medicine. To qualify for the voucher you need to recommend www.vetmedin.co.uk to two separate dog owners being prescribed Vetmedin for congestive heart failure in their pets and then record any feedback at their next appointment. Faxback forms on which to record this feedback are being sent out to all vets around Valentine's Day but extra copies are available from Boehringer direct.
The company says a Vetmedin eCPD professional resource will also be launching on the new site later in the year, featuring an online radiograph viewer, technical dossiers and information on published studies such as QUEST.
Boehringer Ingelheim Vetmedica has launched Prascend, the first licensed product for the treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses, commonly known as Equine Cushing's Disease.
Prascend contains pergolide mesylate, and is supplied in 60 and 160 tablet packs of 1mg tablets.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Many horses and ponies with Cushing's Disease benefit from treatment with pergolide, however, with less than 200 people still being treated with pergolide in the UK, many vets and horse owners have expressed concern that they will not be able access treatment in the future.
"We have invested in dedicated veterinary manufacturing of this product, and can assure our customers that the future supply of Prascend is guaranteed irrespective of any changes of in the human generic market."
For further information, visit www.prascend.co.uk or call 01344 746959
Boehringer Ingelheim Vetmedica has launched a unique and natural muscle building supplement for horses, Equitop Myoplast Power Pearls, containing 18 key amino acids.
The company says maintaining muscular condition in performance and sports horses can be challenging, especially when work load is increased or during periods of convalescence, as feeding high levels of concentrates can often lead to horses becoming 'fizzy' and bulking up on fats and oils.
Scientifically designed to support lean muscle growth, not bulk, Equitop Myoplast Power Pearls is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
The product is endorsed by top British show jumper, Ellen Whitaker and veterinary surgeon and dressage rider, Christel Robbins BVSc MRCVS.
Craig Beck from Boehringer Ingelheim Vetmedica said: "Equitop Myoplast Power Pearls is already one of the most popular equine supplements sold in Germany and is used by top riders in all disciplines to help ensure their horses reach their full athletic potential. We are certain that with the support of riders such as Ellen Whitaker, Equitop Myoplast Power Pearls will prove just as popular in the UK."
Equitop Myoplast Power Pearls is available in a 1.5kg tub (RRP £65) and can be fed separately or mixed with feed. Horses weighing less than 500kg should be fed one scoop (25g) per day, while larger horses should receive two scoops (50g). Boehringer Ingelheim Vetmedica recommends that Equitop Myoplast Power Pearls is fed for at least a month as results are normally visible within 3-4 weeks.
Boehringer Ingelheim Vetmedica is committed to supporting veterinary practices and Equitop Myoplast Power Pearls will be distributed exclusively by veterinary wholesalers. An extensive advertising campaign in professional equine publications will help raise awareness of Equitop Myoplast Power Pearls and, for a limited period, horse owners and equine professionals can download a voucher from http://www.equitop-myoplast.co.uk/ offering a £15 rebate against their first purchase. Veterinary practices can redeem these vouchers by returning them to Boehringer Ingelheim Vetmedica via a freepost address.
For further information on Equitop Myoplast Power Pearls, please contact your local Boehringer Ingelheim Vetmedica representative, visit www.equitop-myoplast.co.uk or call 01344 746959.